AI Article Synopsis
- Acne vulgaris is a widespread inflammatory skin condition that affects people of all ages and can lead to lasting effects like scarring and color changes, which significantly impact mental health.
- Treatment for acne scarring involves various methods including topical creams, physical procedures, and laser therapies, with the best results often seen using a combination of these approaches.
- Trifarotene is a new type of retinoid approved for moderate-to-severe acne in people over 12, showing promise in treating acne scarring by specifically targeting a common receptor in the skin.
Article Abstract
Acne vulgaris is a common, often chronic inflammatory disease that can affect all ages and skin tones. Beyond acute lesions, the sequelae of acne - specifically scarring and dyspigmentation - can be long-lasting, challenging to treat and have substantial psychosocial impact on affected individuals. For acne scarring, treatment modalities include topical, physical, and laser and light therapies, with combination approaches typically yielding optimal outcomes. Trifarotene is a novel fourth generation retinoid with targeted action towards retinoid acid receptor gamma (RAR-γ), the most common isotype found in the epidermis, that has previously been approved for the management of moderate-to-severe facial and truncal acne in individuals over the age of 12 years. Recently, data on trifarotene supports its application in acne scarring. Herein, we provide a succinct review on various treatments for acne scarring and explore how trifarotene and its mechanism of action present an additional topical approach to target atrophic acne scarring.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!